The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties ofl-deprenyl and MDL 72145
- 1 November 1985
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 331 (2-3) , 186-193
- https://doi.org/10.1007/bf00634237
Abstract
The pharmacological properties of two selective inhibitors of monoamine oxidase (MAO) type B,l-deprenyl and MDL 72145 [(E)-2-(3,4-dimethyoxyphenyl)-3-fluoroallylamine, HCl], have been investigated in rats and mice in relation to their effects on MAO. Selective inhibition of MAO B achieved following 18 h pretreatment withl-deprenyl and/or MDL 72145 did not per se lead to prominent pharmacological activity; no effects were seen in the mouse “Behavioural Despair” test, hypothermia induced by reserpine in mice was neither prevented nor reversed and there was no change in the cardiovascular responsiveness of the pithed rat to tyramine, noradrenaline or stimulation of the spinal sympathetic outflow. l-Deprenyl differed from MDL 72145 in that short term treatment with this drug caused positive effects in the “Behavioural Despair” test, reversal of reserpine hypothermia, indirect sympathomimetic stimulation of blood pressure and heart rate in the pithed rat and ipsilateral rotation in rats with unilateral nigro-striatal lesions. Qualitatively similar effects were seen with dexamphetamine. The marked difference between the pharmacological effects of MDL 72145 andl-deprenyl despite equivalent inhibition of MAO B suggests that many of the pharmacological actions ofl-deprenyl result from its amphetaminelike sympathomimetic properties. MDL 72145 can, therefore, be considered a more reliable tool with which to explore the functional importance of MAO B inhibition in experimental animals and man.Keywords
This publication has 34 references indexed in Scilit:
- Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationshipsJournal of Medicinal Chemistry, 1985
- The pharmacology of Parkinson's disease: l-dopa and beyondTrends in Pharmacological Sciences, 1984
- MDL 72145, an Enzyme-Activated Irreversible Inhibitor with Selectivity for Monoamine Oxidase Type BJournal of Neurochemistry, 1984
- Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological, and clinical propertiesMedicinal Research Reviews, 1984
- Deprenyl (selegiline): the history of its development and pharmacological actionActa Neurologica Scandinavica, 1983
- The contribution of amphetamine metabolites of (?)-deprenyl to its antiparkinsonian propertiesJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1982
- Effects of L-deprenyl on human growth hormone secretionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Amphetamine, p-hydroxyamphetamine and β-phenethylamine in mouse brain and urine after (−)- and (+)-deprenyl administrationJournal of Pharmacy and Pharmacology, 1981
- Potentiation by deprenil of l-dopa induced circling in nigral-lesioned ratsPharmacology Biochemistry and Behavior, 1981
- Adverse Effects of Antidepressant Drugs Part 1Drugs, 1981